Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Retinal Vein Occlusion With Anecortave Acetate
NCT00211354Phase 2Withdrawn
- Sponsor
- Manhattan Eye, Ear and Throat Hospital
- Start
- Mar 2002
- Primary completion
- Mar 2007
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anecortave in retinal vein occlusion (RVO), sponsored by Manhattan Eye, Ear and Throat Hospital. Primary endpoint: Investigate the use of anecortave acetate for treatment of retinal vein occlusion at 24 months. Planned start Mar 2002; status: withdrawn.
02
Drugs
anecortave
03
Conditions
retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT00211354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211354.